COVID-19 Vaccine Associated Myopericarditis and Perimyocarditis

See also: CoVid-19 Vaccine Associated Myocarditis and CoVid-19 Vaccine Associated Pericarditis

Myopericarditis refers to inflammation of the pericardium and myocarditis. Myopericarditis is sometimes used interchangeably with perimyocarditis.

Myopericarditis is used when there are primarily pericarditis symptoms with evidence of the involvement of the myocardium as evidenced by cardiac biomarker elevation or imaging studies revealing normal wall motion. If there is evidence of regional wall motion abnormalities with reduced ventricular function, the term perimyocarditis has been used. Manda YR, Baradhi KM. Myopericarditis. [Updated 2021 Jul 26]

Myopericarditis following COVID-19 vaccination: Updates from the Vaccine. Adverse Event Reporting System (VAERS). CDC Aug 30, 2021.

• 2,574 reports of myopericarditis or pericarditis to VAERS (as of August 18, 2021)
  • 1,903 myopericarditis, 671 pericarditis

• Epidemiology of myopericarditis following COVID-19 vaccination similar to previously reported updates
  • Primarily in younger males, after dose 2 mRNA vaccination, symptom onset clustering within several days of vaccination

• Limited follow-up information in VAERS case reports suggests most patients (77%) recovered from symptoms at time of report or follow-up

• Observed vs. Expected analysis with VAERS reports
  • Males: Observed > Expected in age groups through 49 years
  • Females: Observed > Expected in age groups through 29 years

• Enhanced surveillance for myocarditis outcomes after mRNA COVID-19 vaccination in VAERS case reports is ongoing

Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents

Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age

Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents

Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19

Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis

COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis.

Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report

Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male

Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents

Acute myopericarditis after COVID-19 vaccine in adolescents

Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389 .

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083

mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. [[https://www.ncbi.nlm.nih.gov/pubmed/34332972|Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057

Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322

Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report

Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine

Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine

Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine

Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination

Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report

Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine

Perimyocarditis after vaccination with COVID-19

Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol

https://www.ncbi.nlm.nih.gov/pubmed/34270752]Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc

https://www.ncbi.nlm.nih.gov/pubmed/34447639Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus

Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord